| # | Side effect | Count |
|---|---|---|
| 0 | GENERAL PHYSICAL HEALTH DETERIORATION | 6684 |
| 1 | ILL-DEFINED DISORDER | 3641 |
| 2 | DEATH | 1321 |
| 3 | DISEASE PROGRESSION | 360 |
| 4 | MALIGNANT NEOPLASM PROGRESSION | 343 |
| 5 | PROSTATIC SPECIFIC ANTIGEN INCREASED | 287 |
| 6 | LABORATORY TEST ABNORMAL | 266 |
| 7 | FATIGUE | 238 |
| 8 | ANAEMIA | 204 |
| 9 | PLATELET COUNT DECREASED | 168 |
| # | Side effect | Count | Frequency |
|---|---|---|---|
| 0 | POSITRON EMISSION TOMOGRAM PROSTATE | 2 | 0.6667 |
| 1 | COAGULATION FACTOR MUTATION | 1 | 0.2000 |
| 2 | HORMONE-DEPENDENT PROSTATE CANCER | 10 | 0.1429 |
| 3 | HORMONE-REFRACTORY PROSTATE CANCER | 167 | 0.1406 |
| 4 | GASTRIN-RELEASING PEPTIDE PRECURSOR INCREASED | 1 | 0.1000 |
| 5 | ANTERIOR SEGMENT NEOVASCULARISATION | 1 | 0.0833 |
| 6 | NEUROENDOCRINE CANCER OF THE PROSTATE METASTATIC | 1 | 0.0769 |
| 7 | CARCINOID TUMOUR OF THE PROSTATE | 1 | 0.0667 |
| 8 | ILL-DEFINED DISORDER | 3641 | 0.0599 |
| 9 | GENERAL PHYSICAL HEALTH DETERIORATION | 6684 | 0.0577 |